Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cardiac Patients Given Less Blood During Transfusions Do Well

By LabMedica International staff writers
Posted on 24 Dec 2014
Blood transfusion might affect long-term mortality by changing immune function and thus potentially increasing the risk of subsequent infections and cancer recurrence.

Compared with a restrictive transfusion strategy, a more liberal strategy could reduce cardiac complications by lowering myocardial damage, thereby reducing future deaths from cardiovascular disease.

Clinicians at the Robert Wood Johnson Medical School (New Brunswick, NJ, USA) working with colleagues from several other institutions, recruited 2,016 patients from 47 hospitals across the USA and Canada. Patients aged 50 years and older with a hemoglobin concentration lower than 100 g/L within three days after undergoing surgery to repair a hip fracture, and a history of cardiovascular disease or risk factors for cardiovascular disease were enrolled in the randomized controlled trial. Half of the patients received larger quantities of transfused blood; and the other half received transfusions that were smaller by as much as two thirds.

The total population of 2,016 enrolled patients had a mean age of 81.6 years (range 5 to 103 years), 1,527 (76%) were women, and 1,268 (63%) had cardiovascular disease. The mean pre-transfusion hemoglobin concentration was 92 ± 5 g/L in the liberal transfusion strategy group and 79 ± 6 g/L in the restrictive transfusion strategy group. The number of units of red blood cells transfused post-randomization in the liberal transfusion strategy was 2.9-times larger than that in the restrictive transfusion strategy. Long-term mortality did not differ significantly between the two treatment groups as 432 (43.2%) of 999 patients died in the liberal transfusion strategy group and 409 (40.8%) of 1,003 died in the restrictive strategy group. The cause of death did not differ between the transfusion strategies and the proportion of deaths from cardiovascular disease, cancer, and infections were nearly identical in the two groups of the trial.

Jeffrey L. Carson, MD, a professor and lead author of the study said, “Physicians performing surgeries and other procedures judge whether blood is needed based on how much they have seen the patient lose and by closely watching vital signs such as blood pressure. If physicians overestimate and provide too much blood, the patient's circulatory system can be overloaded and breathing can be affected. The risk of infection can also increase. There are definite risks associated with transfusion. The classic ones are hepatitis and human immunodeficiency virus (HIV). They are as rare as being hit by lightning, but even so, why give more blood to anyone if you can't show it benefits them?” The study was published on December 9, 2014, in the journal the Lancet.

Related Links:

Robert Wood Johnson Medical School 



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.